What Psychiatric Times Got Right About Cobenfy — and Why Switching Matters

When I read the recent Psychiatric Times reflection on the first year of Cobenfy in real-world practice, I found myself agreeing with much of what was said because the article finally acknowledged what many of us have learned the hard way: the medication itself has not been the limiting factor. Implementation has (Weiden, 2026).

WVE-007 and the Expanding Role of Metabolic Treatments in Mental Health Care

The landscape of metabolic medicine has changed significantly over the past several years, largely driven by the impact of GLP-1 receptor agonists.

A New Wave in Depression Treatment: GlyphAllo Enters Phase 2b for MDD With and Without Anxious Distress

For decades, we've grappled with the challenge of treating major depressive disorder (MDD)—particularly in clients who also experience anxious distress. Add to that the limitations of current treatments, delayed onset of action, and tolerability issues, and it’s no wonder that innovation in this space is urgently needed

Newest Psychiatric Treatments for Generalized Anxiety Disorder (GAD)

There are few drugs that are Food and Drug Administration (FDA) indicated first line for Generalized Anxiety Disorder (GAD). Selective Serotonin Inhibitors (SSRIs) such as Lexapro (escitalopram), approved in 2005, and Paxil (paroxetine), approved in 1999, by the FDA.

Caplyta in Bipolar Depression: When Efficacy Meets Tolerability

The conversation around lumateperone (Caplyta) in bipolar depression has become more nuanced with new data and, frankly, more complicated in clinical practice. A recent meta-analysis in the Journal of Psychopharmacology confirmed what many of us already knew at the bedside:

GM-2505: A Promising Advancement in the Treatment of Major Depressive Disorder